ENB-106

N/A

Report date: 2024/07/24 17:42:03
NME

Base Information

Drug NameENB-106
Drug Alias NameENB-106ENB106
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsDiabetic macular oedemaAcute Kidney InjuryMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai EnnovaBio Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai EnnovaBio Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaAcute Kidney InjuryMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A